- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07945314
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
A Phase 1, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
The main purpose of this study is to see if LY3839056 is safe and well tolerated when given as a single dose into a vein intravenous (IV) or under the skin subcutaneous (SC) in healthy participants. The study will also measure how much LY3839056 gets into the blood and how long it takes the body to remove it. The study will last up to 17 weeks and includes a stay of about 6 days at the clinical research unit.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: 1-877-CTLILLY (1-877-285-4559) or
- Telefoonnummer: 1-317-615-4559
- E-mail: LillyTrials@lilly.com
Studie Locaties
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200040
- Huashan Hospital, Fudan University (复旦大学附属华山医院) 12 Urumqi Middle Road
-
Contact:
- Xiaojie Wu, PhD
- Telefoonnummer: 13524686330
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and Cardiac Monitoring.
- Have clinical laboratory test results within normal reference range for the population or the clinical research site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.
- Have venous access sufficient to allow for IV drug delivery and blood sampling as per the protocol.
- Have a body mass index within the range of 18.0 to 32.0 kg/m².
- Participants assigned male or female at birth, including individuals of childbearing potential (IOCBP), may participate in this trial.
- Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Key Exclusion Criteria:
- Are immunocompromised or have a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection.
- Have a history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders.
- Had any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or any planned surgical procedure scheduled to occur during the study.
- Have a clinically significant history of multiple or severe allergies or an anaphylactic reaction to prescription or nonprescription drugs or food.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Cohort 1 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andere namen:
|
|
Experimenteel: Cohort 2 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andere namen:
|
|
Experimenteel: Cohort 3 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andere namen:
|
|
Experimenteel: Cohort 4a IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andere namen:
|
|
Experimenteel: Cohort 4b SC
Participants will receive LY3839056 Subcutaneously |
LY3839056 Administered Subcutaneously
Andere namen:
|
|
Experimenteel: Cohort 5 IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andere namen:
|
|
Experimenteel: Cohort 6a IV
Participants will receive LY3839056 Intravenously |
LY3839056 Administered Intravenously
Andere namen:
|
|
Experimenteel: Cohort 6b SC
Participants will receive LY3839056 Subcutaneously |
LY3839056 Administered Subcutaneously
Andere namen:
|
|
Placebo-vergelijker: Placebo IV
Participants will receive Placebo Intravenously |
Placebo Administered Intravenously
Andere namen:
|
|
Placebo-vergelijker: Placebo SC
Participants will receive Placebo Subcutaneously |
Placebo Administered Subcutaneously
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To evaluate the safety and tolerability of LY3839056 following single-dose administration (IV or SC) in healthy participants.
Tijdsspanne: Baseline through Day 85
|
Frequency of AEs, TEAEs, SAEs, and Discontinuation due to TEAEs. |
Baseline through Day 85
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
PK: Cmax
Tijdsspanne: Predose on Day 1 up to Day 85
|
Maximum Observed Concentration (Cmax) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: AUC
Tijdsspanne: Predose on Day 1 up to Day 85
|
Area Under the Concentration Versus Time Curve (AUC) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: t1/2
Tijdsspanne: Predose on Day 1 up to Day 85
|
Half Life (t1/2) of LY3839056 following single SC or IV dose |
Predose on Day 1 up to Day 85
|
|
PK: F%
Tijdsspanne: Predose on Day 1 up to Day 85
|
Bioavailability (F%) of LY3839056 following single SC dose |
Predose on Day 1 up to Day 85
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- 27924
- J7H-MC-KAAB (Andere identificatie: Eli Lilly and Company)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .